SVB Leerink

Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

Retrieved on: 
Thursday, August 18, 2022
Health, Technology, Health Technology, Software, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Compte rendu, Multimedia, Internal medicine, AllianceBernstein, Private Securities Litigation Reform Act, Technology, Growth, BTG, Security (finance), Research, Method, COVID-19, Twitter, Drug design, Acquisition, Strategic planning, Therapy, Vaccine, Biotechnology, BTG (company), Drug development, Blog, Risk, SVB Leerink, Harvard Business School, University, Nasdaq, LinkedIn, Management, Risk management, Merck

Schrdinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer.

Key Points: 
  • Schrdinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer.
  • Dr. Porges brings to Schrdinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry.
  • View the full release here: https://www.businesswire.com/news/home/20220818005061/en/
    Schrdinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer.
  • (Photo: Business Wire)
    Geoff is a proven leader in the biopharmaceutical and investment industries and has been one of the most respected analysts covering biopharma, said Ramy Farid, Ph.D., chief executive officer at Schrdinger.

LetsGetChecked Completes Acquisition of BioIQ

Retrieved on: 
Tuesday, May 3, 2022
Technology, Insurance, Professional Services, Software, Other Health, Internet, Managed Care, Health, General Health, EU, United Kingdom, Veritas Genetics, Credit Suisse, SVB Leerink, Cooley LLP, Industry, Genomics, Government, Health, LLP, Public health, CLIA, Population health, Solution, News, CEO, Acquisition, Health insurance

Today, LetsGetChecked, a leading global healthcare solutions company, announced it has finalized the acquisition of BioIQ, an analytics-driven population health and diagnostics company.

Key Points: 
  • Today, LetsGetChecked, a leading global healthcare solutions company, announced it has finalized the acquisition of BioIQ, an analytics-driven population health and diagnostics company.
  • With this acquisition, LetsGetChecked gains a trusted partner with an extensive knowledge base and a breadth of experience in serving health plans and employer markets to deliver healthcare solutions at scale.
  • As a result of this acquisition, BioIQs consumers, health plan, government, and employer customers will have access to an even wider-reaching, best-in-class virtual care experience.
  • As previously announced, BioIQ will operate as a wholly-owned subsidiary of LetsGetChecked.

Patient Square Capital Announces the Formation of Enavate Sciences to Invest in and Support Therapeutic Companies

Retrieved on: 
Monday, May 2, 2022
Board, Investment, Director, Silicon Valley Bank, Medicine, Biotechnology, SVB Leerink, Investment banking, CFO, Drug discovery, Patient, Partnership, Environment, Therapy, SVB, Health, Quality of life, ENAV, Science, Merrill (company), CEO, Technology, Growth, Pharmaceutical industry

MENLO PARK, Calif., May 2, 2022 /PRNewswire/ -- Patient Square Capital ("Patient Square"), a leading dedicated health care investment firm, today announced the formation of a new portfolio company, Enavate Sciences, to invest in and enable the growth of therapeutic and enabling technology companies. Enavate has received an initial capital commitment of $300 million from Patient Square and anticipates significant additional funding to be raised over time.

Key Points: 
  • MENLO PARK, Calif., May 2, 2022 /PRNewswire/ -- Patient Square Capital ("Patient Square"), a leading dedicated health care investment firm, today announced the formation of a new portfolio company, Enavate Sciences , to invest in and enable the growth of therapeutic and enabling technology companies.
  • Enavate has received an initial capital commitment of $300 million from Patient Square and anticipates significant additional funding to be raised over time.
  • There are many promising companies with innovative science, however, that do not fit this model," said Jim Momtazee, Managing Partner of Patient Square and Chairman of the Board of Directors of Enavate Sciences.
  • Enavate Sciences is a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient need.

Delivering Comprehensive Financial Services to the Innovation Economy, SVB Financial Group Rebrands to Reflect Growth

Retrieved on: 
Tuesday, April 19, 2022
CEO, SVB Leerink, Mirae Asset Financial Group, Silicon, Social responsibility, SIPC, Probability, Goal, FDIC, Investment, Silicon Valley Bank, SVB, Technology, SEC, Federal Reserve, Chevron, Structure of the Federal Reserve System, FINRA, Multimedia, SIVB, Partnership, Acquisition, View, Trust, Renewable energy, Financial services

SANTA CLARA, Calif., April 19, 2022 /PRNewswire/ -- SVB Financial Group (SVB), the financial partner of the innovation economy, today announced a rebrand of its four primary businesses — Silicon Valley Bank, SVB Capital, SVB Private and SVB Securities — under the brand name SVB.

Key Points: 
  • "SVB" to represent the company's full offering:
    SANTA CLARA, Calif., April 19, 2022 /PRNewswire/ --SVB Financial Group (SVB), the financial partner of the innovation economy, today announced a rebrand of its four primary businesses Silicon Valley Bank, SVB Capital, SVB Private and SVB Securities under the brand name SVB .
  • SVB Private, formerly SVB Private Bank, manages $19.6 billion in assets for clients following the acquisition of Boston Private in 2021.
  • While SVB will go to market under the SVB brand name, SVB Financial Group remains the legal entity name of the holding company.
  • SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, SVB SECURITIES, SVB PRIVATE, SVB CAPITAL and the chevron device are trademarks of SVB Financial Group, used under license.

Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering

Retrieved on: 
Monday, April 18, 2022
808, Annual report, SVB Leerink, Telephone, Park, LLC, U.S. Securities and Exchange Commission, State Street, Security (finance), Hyperinsulinism, Research, Attention, Congenital adrenal hyperplasia, Acromegaly, Drug discovery, Equity capital markets, GLOBE, SST2, Securities Act of 1933, Degenerative disease, Sale, Form 10-K, SAN, Securities Exchange Act of 1934, 4th floor, Prospectus, Nasdaq, Cantor, SEC, Wilms' tumor, Medication, Therapy, Carcinoid syndrome, ACTH, Pharmaceutical industry

The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $125.0 million.

Key Points: 
  • The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $125.0 million.
  • The offering included new investors, Braidwell and Suvretta Capital Managements Averill strategy, as well as participation from existing stockholders.
  • JMP Securities, a Citizens Company, and H.C. Wainwright & Co. acted as co-lead managers and JonesTrading acted as co-manager for the offering.
  • Crinetics Pharmaceuticals is also developing paltusotine for the treatment of carcinoid syndrome associated with neuroendocrine tumors.

Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, April 18, 2022
808, SVB Leerink, Kitchen Party (girl group), Biotechnology, Telephone, Wells Fargo, LLC, U.S. Securities and Exchange Commission, Security (finance), State Street, Peachtree Road, Attention, GLOBE, Sale, Risk, Patient, Madison Avenue, Prospectus, SEC, Forward-looking statement, Affimer, Jefferies Group, Exercise, Cancer

The exercise of the option to purchase over-allotment shares brought the total number of common shares sold by Affimed to 25,875,000 common shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by Affimed, to $103.5 million.

Key Points: 
  • The exercise of the option to purchase over-allotment shares brought the total number of common shares sold by Affimed to 25,875,000 common shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by Affimed, to $103.5 million.
  • Jefferies LLC, SVB Leerink, Truist Securities, Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers and Berenberg Capital Markets LLC is acting as a co-manager of the offering.
  • A prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available at the SECs website located at www.sec.gov.
  • This press release contains statements that constitute forward-looking statements, including with respect to the proposed offering of common shares and the anticipated use of the net proceeds.

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

Retrieved on: 
Wednesday, April 13, 2022
808, Annual report, SVB Leerink, Telephone, Park, LLC, U.S. Securities and Exchange Commission, State Street, Security (finance), Hyperinsulinism, Research, Attention, Congenital adrenal hyperplasia, Acromegaly, Drug discovery, Equity capital markets, GLOBE, SST2, Securities Act of 1933, Degenerative disease, Sale, Form 10-K, SAN, Securities Exchange Act of 1934, 4th floor, Prospectus, Nasdaq, Cantor, SEC, Wilms' tumor, Medication, Therapy, Carcinoid syndrome, ACTH, Pharmaceutical industry

All of the shares to be sold in the offering are to be sold by Crinetics.

Key Points: 
  • All of the shares to be sold in the offering are to be sold by Crinetics.
  • The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million.
  • The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary closing conditions.
  • SVB Leerink, Evercore ISI and Cantor are acting as joint bookrunning managers for the offering.

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares

Retrieved on: 
Wednesday, April 13, 2022
808, SVB Leerink, Kitchen Party (girl group), Biotechnology, Telephone, Wells Fargo, Media, LLC, U.S. Securities and Exchange Commission, Security (finance), State Street, Peachtree Road, Attention, GLOBE, Sale, Risk, Patient, Madison Avenue, Prospectus, SEC, Forward-looking statement, Affimer, Jefferies Group, Media contacts database, Cancer

HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (Affimed or the Company), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share.

Key Points: 
  • HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (Affimed or the Company), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share.
  • In addition, Affimed has granted the underwriters a 30-day over-allotment option to purchase up to 3,375,000 common shares at the public offering price less underwriting discounts.
  • After deducting the underwriting discounts, the net proceeds of the public offering are expected to be $84.6 million.
  • The offering is expected to close on or about April 18, 2022, subject to customary closing conditions.

Affimed Announces Proposed Public Offering of Common Shares

Retrieved on: 
Tuesday, April 12, 2022
808, SVB Leerink, Kitchen Party (girl group), Biotechnology, Telephone, Wells Fargo, Media, LLC, U.S. Securities and Exchange Commission, Security (finance), State Street, Peachtree Road, Attention, GLOBE, Sale, Risk, Patient, Madison Avenue, Prospectus, Company, SEC, Forward-looking statement, Affimer, Jefferies Group, Media contacts database, Cancer

HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (Affimed or the Company), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has commenced an underwritten public offering of common shares.

Key Points: 
  • HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (Affimed or the Company), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has commenced an underwritten public offering of common shares.
  • The Company expects to grant the underwriters a 30-day over-allotment option to purchase up to 15 percent of the number of common shares sold in connection with the offering.
  • All of the shares in the offering will be sold by Affimed.
  • This press release contains statements that constitute forward-looking statements, including with respect to the proposed offering of common shares and the anticipated use of the net proceeds.

Selecta Biosciences Announces $38.7 Million Underwritten Offering

Retrieved on: 
Wednesday, April 6, 2022
808, Private Securities Litigation Reform Act, S-3, Sale, Form, Canaccord Genuity, Attention, SEC, Telephone, U.S. Securities and Exchange Commission, Prospectus, LLC, Selecta, State Street, Nasdaq, GLOBE, SVB Leerink, Annual report, SEC filing, Security (finance)

All of the securities in the offering will be sold by Selecta.

Key Points: 
  • All of the securities in the offering will be sold by Selecta.
  • The gross proceeds to Selecta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $38.7 million.
  • The offering is expected to close on April 11, 2022, subject to the satisfaction of customary closing conditions.
  • Selecta Biosciences, Inc. is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.